KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$162.3 million.

  • Recursion Pharmaceuticals' Profit After Tax fell 6929.22% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 8942.19%. This contributed to the annual value of -$463.7 million for FY2024, which is 4133.16% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Profit After Tax stood at -$162.3 million, which was down 6929.22% from -$171.9 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Profit After Tax high stood at -$30.7 million for Q1 2021, and its period low was -$202.5 million during Q1 2025.
  • For the 5-year period, Recursion Pharmaceuticals' Profit After Tax averaged around -$92.3 million, with its median value being -$76.7 million (2023).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Profit After Tax plummeted by 15201.04% in 2021 and then skyrocketed by 1145.95% in 2022.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Profit After Tax stood at -$64.9 million in 2021, then grew by 11.46% to -$57.5 million in 2022, then plummeted by 61.75% to -$93.0 million in 2023, then crashed by 92.38% to -$178.9 million in 2024, then increased by 9.31% to -$162.3 million in 2025.
  • Its last three reported values are -$162.3 million in Q3 2025, -$171.9 million for Q2 2025, and -$202.5 million during Q1 2025.